Literature DB >> 29891598

Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance.

Ryan K Shields1,2, M Hong Nguyen3,2, Binghua Hao2, Ellen G Kline1, Cornelius J Clancy1,4.   

Abstract

We tested ceftazidime-avibactam and colistin against 24 carbapenem-resistant Enterobacteriaceae (CRE) isolates by time-kill studies. Ceftazidime-avibactam at 0.25×, 1×, and 4× the MIC was bactericidal against 8%, 21%, and 88% of the isolates, respectively. Colistin (2 μg/ml) was bactericidal against 83% (12 h) and 42% (24 h) of the isolates. In combination, synergy and antagonism were identified against 13% and 46% of the isolates, respectively. The combination did not suppress ceftazidime-avibactam resistance. Colistin plus ceftazidime-avibactam did not provide a benefit over ceftazidime-avibactam against most CRE isolates.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  CRE; Klebsiella; Klebsiella pneumoniae; antagonism; ceftazidime-avibactam; colistin; synergy

Mesh：

Substances：

Year:  2018        PMID： 29891598      PMCID： PMC6105820          DOI： 10.1128/AAC.01018-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae.

Authors:  Sarath Nath; Farzad Moussavi; Daniel Abraham; David Landman; John Quale
Journal:  J Antimicrob Chemother       Date:  2018-02-01       Impact factor: 5.790

2.  Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Ryan K Shields; Cornelius J Clancy; Ellen G Press; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  In vivo evolution to colistin resistance by PmrB sensor kinase mutation in KPC-producing Klebsiella pneumoniae is associated with low-dosage colistin treatment.

Authors:  Antonio Cannatelli; Vincenzo Di Pilato; Tommaso Giani; Fabio Arena; Simone Ambretti; Paolo Gaibani; Marco Maria D'Andrea; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

4.  Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients.

Authors:  C J Clancy; L Chen; R K Shields; Y Zhao; S Cheng; K D Chavda; B Hao; J H Hong; Y Doi; E J Kwak; F P Silveira; R Abdel-Massih; T Bogdanovich; A Humar; D S Perlin; B N Kreiswirth; M Hong Nguyen
Journal:  Am J Transplant       Date:  2013-09-06       Impact factor: 8.086

5.  In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Liang Chen; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

6.  Multiplex real-time PCR for detection of an epidemic KPC-producing Klebsiella pneumoniae ST258 clone.

Authors:  Liang Chen; Kalyan D Chavda; José R Mediavilla; Yanan Zhao; Henry S Fraimow; Stephen G Jenkins; Michael H Levi; Tao Hong; Albert D Rojtman; Christine C Ginocchio; Robert A Bonomo; Barry N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

7.  Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.

Authors:  Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Brian A Potoski; Rachel V Marini; Yohei Doi; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

8.  A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β-lactams in Pseudomonas aeruginosa.

Authors:  Cédric Muller; Patrick Plésiat; Katy Jeannot
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

9.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; Brian A Potoski; Ghady Haidar; Binghua Hao; Yohei Doi; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2016-09-13       Impact factor: 9.079

10.  Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Liang Chen; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Open Forum Infect Dis       Date:  2017-07-01       Impact factor: 3.835
View more
  8 in total

Review 1.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

2.  Comparative Antibiofilm Efficacy of Meropenem Alone and in Combination with Colistin in an In Vitro Pharmacodynamic Model by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae.

Authors:  Alba Ribera; Eva Benavent; Cristina El-Haj; Joan Gomez-Junyent; Fe Tubau; Raul Rigo-Bonnin; Javier Ariza; Oscar Murillo
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 3.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

4.  Ceftazidime-avibactam and intrapleural amikacin therapy for extensively drug-resistant Pseudomonas aeruginosa thoracic empyema: A case report.

Authors:  Tzu-Ting Chen; Shu-Mei Chen; Hsin-Yi Liu
Journal:  Medicine (Baltimore)       Date:  2022-06-17       Impact factor: 1.817

5.  In silico genome-scale metabolic modeling and in vitro static time-kill studies of exogenous metabolites alone and with polymyxin B against Klebsiella pneumoniae.

Authors:  Wan Yean Chung; Nusaibah Abdul Rahim; Mohd Hafidz Mahamad Maifiah; Naveen Kumar Hawala Shivashekaregowda; Yan Zhu; Eng Hwa Wong
Journal:  Front Pharmacol       Date:  2022-08-04       Impact factor: 5.988

6.  A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.

Authors:  Courtney L Luterbach; Hongqiang Qiu; Patrick O Hanafin; Rajnikant Sharma; Joseph Piscitelli; Feng-Chang Lin; Jenni Ilomaki; Eric Cober; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Roger L Nation; Robert A Bonomo; Cornelia B Landersdorfer; David van Duin; Gauri G Rao
Journal:  Antimicrob Agents Chemother       Date:  2022-09-20       Impact factor: 5.938

7.  In vitro Synergistic Activity of Antimicrobial Combinations Against bla KPC and bla NDM-Producing Enterobacterales With bla IMP or mcr Genes.

Authors:  Chaoe Zhou; Qi Wang; Longyang Jin; Ruobing Wang; Yuyao Yin; Shijun Sun; Jiangang Zhang; Hui Wang
Journal:  Front Microbiol       Date:  2020-10-21       Impact factor: 5.640

8.  Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing K. pneumoniae Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside.

Authors:  Alessandra Oliva; Ambrogio Curtolo; Lorenzo Volpicelli; Francesco Cogliati Dezza; Massimiliano De Angelis; Sara Cairoli; Donatella Dell'Utri; Bianca Maria Goffredo; Giammarco Raponi; Mario Venditti
Journal:  Antibiotics (Basel)       Date:  2021-06-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.